B-cell lymphoma 2-related protein A1 (BCL2A1)

B-cell lymphoma 2-related protein A1 (BCL2A1) is an anti-apoptotic member of the BCL-2 family that prevents programmed cell death by sequestering pro-apoptotic proteins and blocking cytochrome c release from mitochondria[1][3]. It is predominantly expressed in the hematopoietic system, where it is regulated by inflammatory signals and nuclear factor kappa B (NF-κB)[1][2][3]. BCL2A1 is upregulated in various cancers and contributes to both tumor progression and resistance to chemotherapy by promoting cell survival[1]. Its expression can be induced by cytokines such as GM-CSF, TNF, and IL-1, as well as signaling pathways including CD40 and PI3K/ERK[2][3]. Because of its role in cell survival and apoptosis blockade, BCL2A1 is considered a potential therapeutic target, especially in cancer therapy aimed at sensitizing tumor cells to apoptosis[1]. BCL2A1, through complex protein interactions, exerts a cytoprotective function essential for immune system homeostasis and survival, but its overexpression is frequently implicated in oncogenesis and therapy resistance[1][3]. Experimental small molecule inhibitors of BCL2A1 are under evaluation, but none are yet clinical standard[1]. Careful consideration is needed in targeting BCL2A1 due to its physiological role in normal hematopoietic cell survival[1].

Other names

BCL2L5BFL1GRSHBPA1ACC-1ACC-2ACC1ACC2Bcl2-L-5Bcl-2-like protein 5bcl-2-related protein A1hematopoietic BCL2-related protein A1hemopoietic-specific early response proteinprotein BFL-1protein GRS

Inhibition of BCL2A1 sensitizes tumor cells to apoptosis and chemotherapeutic agents by blocking its anti-apoptotic function[1].